A Phase 1 interventional study of VIS649 and Placebo in Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy and IgA Nephropathy, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Glomerulonephritis, IGA with a site in United States — 25 open to participants now, 37 under way, 16 of them phase 3. Glomerulonephritis, IGA · United States.
Among the 73 studies in Glomerulonephritis, IGA with a site in United States, this one is the 39th largest by enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2018, is one of 3 in phase 1, and was the 21st registered.
276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.
Browse Glomerulonephritis, IGA studies →25 of the 73 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:
Jade Biosciences, Inc. · Sites in United States
Ages 18+
argenx · Sites in United States, Japan
Ages 18+
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Novartis Pharmaceuticals · Sites in United States, China, Colombia and 5 more countries
Ages 2–18
Akebia Therapeutics · Sites in United States, Brazil
Ages 16+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 33 · Phase 3 22 · Phase 4 7
First in 1997; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.
Median enrollment 67 across the 67 interventional studies, 744 across the 6 observational. Of the 34 that completed or were terminated, 25 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 6 studies filed under Glomerulonephritis, IGA — fewer than ten, so there is no comparison to draw.
8 of the studies in Glomerulonephritis, IGA with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06935357Phase 3BiogenA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | 2027-05-31 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06712407Calliditas Therapeutics ABEfficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy | 2027-03 |
| NCT06466135Walden BiosciencesStudy of WAL0921 in Patients With Glomerular Kidney Diseases | 2027-03 |
| NCT05003986Travere Therapeutics, Inc.Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases | 2027-03-12 |
Add all 8 to your calendar (.ics) → With an account.
Among the 73 studies in Glomerulonephritis, IGA with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 1, randomized, placebo-controlled, double-blind, single ascending dose study of IV VIS649 in healthy subjects.
VIS649 is a monoclonal immunoglobulin G2 (IgG2) antibody targeting the B-cell growth factor APRILL.
The study will enroll up to 45 subjects and will be conducted in up to 5 sequential dosing cohorts at four different dose levels, enrolling 9 subjects per cohort. Subjects will be randomized to VIS649 or placebo in a ratio of 7:2 (7 active, 2 placebo). Safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from the initial cohorts will be assessed.
On Day 1, a single dose of VIS649 or placebo will be administered IV. Pharmacokinetics sampling will start with a collection prior to the start of infusion and at multiple timepoints throughout the study. Pharmacodynamics sampling will occur at baseline and multiple timepoints throughout the study.
Sentinel subjects will be utilized; the first two subjects in each cohort will be randomized to receive either VIS649 or placebo and will receive study drug at least 24 hours before the remaining subjects in the cohort are dosed.
The safety profile of these subjects over the 24 hour post-administration period will be reviewed to determine whether it is appropriate to proceed with enrollment of the remaining subjects in the cohort as planned. This will occur for each dose escalation.
The maximum duration of participation (Screening through End-of-study) for individual subjects will be approximately 20 weeks (5 months). The scheduled final visit will occur 16 weeks post-dosing (112 days).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The following applies to female subjects:
Screening laboratory values must meet the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of VIS649 will be administered IV over approximately 1 hour on Day 1, at doses ranging from 0.5 mg/kg up to but not to exceed 20 mg/kg. No other doses will be administered during the study.
Biological: VIS649
Single IV dose of placebo will be administered via IV over approximately 1 hour on Day 1. No other doses will be administered during the study.
Biological: Placebo
Single IV dose of study product on Day 1 of study
Singe IV dose of placebo administered via IV on Day 1 of study
Overall Summary of Treatment Emergent Adverse Events
The number adverse events (AEs), serious adverse events (SAEs), and drug related events following administration of VIS649. Safety will be assessed via AE severity per CTCAE v4.0
Time frame: Baseline to day 112
Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participants
The maximum serum concentration (Cmax) of VIS649 determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants
Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participant
The time to the maximum serum concentration (tmax) of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants
Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
The Pharmacokinetic Exposure Profiles of VIS649 in Serum. All Participants
Summary of the pharmacokinetic profiles of VIS649 exposure in serum for all participants. AUC0-112 presents the area under the concentration time curve from pre-dose (time 0) to the concentration on day 112. AUC0-last presents the area under the concentration time curve from pre-dose (time 0) to the last quantifiable concentration. AUC0-inf presents the area under the concentration time curve from pre-dose (time 0) extrapolated to infinite time.
Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
T 1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. All Participants
The terminal elimination half life (t1/2) of VIS649 from the concentration-time profile as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.
Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose.
The clearance rate (CL) of VIS649 using the exposure calculated to infinity of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants.
Time frame: Day 1 to day 112
Vd: The Volume of Distribution of VIS649 in Serum Samples. All Participants
The volume of distribution of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants.
Time frame: Day 1 to day 112
Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Time Profile. Japanese Participants
The maximum serum concentration (Cmax) of VIS649 determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. Japanese participants
Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Japanese Participants
The time to the maximum serum concentration (tmax) of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. Japanese participants.
Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
The Pharmacokinetic Exposure Profiles of VIS649 in Serum. Japanese Participants
AUC0-112 presents the area under the concentration time curve from pre-dose (time 0) to the concentration on day 112. AUC0-last presents the area under the concentration time curve from pre-dose (time 0) to the last quantifiable concentration. AUC0-inf presents the area under the concentration time curve from pre-dose (time 0) extrapolated to infinite time.
Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
T1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. Japanese Participants
The terminal elimination half life (t1/2) of VIS649 from the concentration-time profile as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.
Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. Japanese Participants
The clearance rate (CL) of VIS649 using the exposure calculated to infinity of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.
Time frame: Day 1 to day 112.
Vd: The Volume of Distribution of VIS649 in Serum Samples. Japanese Participants
The volume of distribution of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.
Time frame: Day 1 to day 112.
Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Non-Japanese Participants
The maximum serum concentration (Cmax) of VIS649 determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.
Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Non-Japanese Participants
The time to the maximum serum concentration (tmax) of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.
Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
The Pharmacokinetic Exposure Profiles of VIS649 in Serum. Non-Japanese Participants
Summary of the pharmacokinetic profiles of VIS649 exposure in serum for non-Japanese participants. AUC0-112 presents the area under the concentration time curve from pre-dose (time 0) to the concentration on day 112. AUC0-last presents the area under the concentration time curve from pre-dose (time 0) to the last quantifiable concentration. AUC0-inf presents the area under the concentration time curve from pre-dose (time 0) extrapolated to infinite time.
Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
T1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. Non-Japanese Participants
The terminal elimination half life (t1/2) of VIS649 from the concentration-time profile as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. Non-Japanese participants.
Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. Non-Japanese Participants
The clearance rate (CL) of VIS649 using the exposure calculated to infinity of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.
Time frame: Day 1 to day 112.
Vd: The Volume of Distribution of VIS649 in Serum Samples. Non-Japanese Participants
The volume of distribution of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.
Time frame: Day 1 to day 112.
Pharmacodynamic Effect of VIS649 on Total Immunoglobulin G Species. All Participants
The effect of VIS649 treatment on total IgG levels in serum, weekly observations from baseline to Week 24
Time frame: From baseline to Week 24
Pharmacodynamic Effect of VIS649 on Total Immunoglobulin A Species. All Participants
The effect of VIS649 treatment on total IgA levels in serum, weekly observations from Baseline to Week 24
Time frame: From baseline to Week 24
Pharmacodynamic Effect of VIS649 on Total Immunoglobulin M Species. All Participants
The effect of VIS649 treatment on total IgM levels in serum, weekly observations from Baseline to Week 24
Time frame: From baseline to Week 24
Pharmacodynamic Effect of VIS649 on Circulating CD16 +CD56 (Natural Killer) Cells for All Participants in Cohorts 1-4
The effect of VIS649 treatment on the population of circulating CD16 +CD56 (Natural killer) cells in serum for all participants in cohorts 1-4.
Time frame: From baseline to Week 24
Pharmacodynamic Effect of VIS649 on Circulating CD19 (B Cells) for All Participants in Cohorts 1-4
The effect of VIS649 treatment on the population of circulating CD19 (B Cells) in serum for all participants in cohorts 1-4.
Time frame: From baseline to Week 24
Pharmacodynamic Effect of VIS649 on Circulating CD4 T Cells for All Participants in Cohorts 1-4
The effect of VIS649 treatment on the population of circulating CD4 T cells in serum for all participants in cohorts 1-4.
Time frame: From baseline to Week 24
Pharmacodynamic Effect of VIS649 on Circulating CD3 T Cells for All Participants in Cohorts 1-4
The effect of VIS649 treatment on the population of circulating CD3 T cells in serum for all participants in cohorts 1-4.
Time frame: From baseline to Week 24
Pharmacodynamic Effect of VIS649 on Circulating CD8 T Cells for All Participants in Cohorts 1-4
The effect of VIS649 treatment on the population of circulating CD8 T cells in serum for all participants in cohorts 1-4.
Time frame: From baseline to Week 24
Summary of Anti -VIS649 Anti-drug Antibodies (ADA)
Summary of Anti -VIS649 anti-drug antibodies (ADA) by treatment group, all participants
Time frame: Baseline to Day 112
Summary of Anti -VIS649 Antibody (ADA) Titer by Treatment
Summary of Anti -VIS649 antibody (ADA) titer by treatment, all participants with ADA positive results
Time frame: Baseline to Day 112
Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participants by Anti-VIS649 Status
The maximum serum concentration (Cmax) of VIS649 determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 status (positive or negative).
Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participants by Anti-VIS649 Status
The time to the maximum serum concentration (tmax) of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 status (positive or negative).
Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
The Pharmacokinetic Exposure Profiles of VIS649 in Serum Samples, All Participants by Anti-VIS649 Antibody Status.
Summary of the pharmacokinetic profiles of VIS649 exposure in serum for all participants based on their anti-VIS649 antibody status (negative/positive). AUC0-112 presents the area under the concentration time curve from pre-dose (time 0) to the concentration on day 112. AUC0-last presents the area under the concentration time curve from pre-dose (time 0) to the last quantifiable concentration. AUC0-inf presents the area under the concentration time curve from pre-dose (time 0) extrapolated to infinite time.
Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
T1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. All Participants by Anti-VIS649 Antibody Status.
The terminal elimination half life (t1/2) of VIS649 from the concentration-time profile as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 antibody status (negative/positive).
Time frame: 0, 1, 2, 8, and 24-hours post-dose, Day 3, 7, 14, 28, 42, 56, 70, and 112.
CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. All Participants by Anti-VIS649 Antibody Status.
The clearance rate (CL) of VIS649 using the exposure calculated to infinity of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 antibody status (positive or negative)..
Time frame: 112 days
Vd: The Volume of Distribution of VIS649 in Serum Samples. All Participants by Anti-VIS649 Antibody Status (Positive or Negative)
The calculated volume of distribution of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 antibody status (positive or negative).
Time frame: 112 days
Recruitment was done for a single clinical site.
| Milestone | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | Placebo Cohort 5 + Vaccine | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|---|---|
| Started | 8 | 7 | 7 | 7 | 7 | 5 | 10 |
| Completed | 8 | 7 | 5 | 7 | 6 | 5 | 9 |
| Not completed | 0 | 0 | 2 | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
The number adverse events (AEs), serious adverse events (SAEs), and drug related events following administration of VIS649. Safety will be assessed via AE severity per CTCAE v4.0
| Event | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | Placebo Cohort 5 + Vaccine | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|---|---|
| Adverse Events | 8 | 3 | 7 | 7 | 7 | 6 | 4 |
| Serious Adverse Events | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Drug related events | 3 | 2 | 3 | 3 | 1 | 1 | 0 |
| Mild severity | 4 | 2 | 2 | 1 | 3 | 3 | 4 |
| Moderate severity | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Severe severity | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
The maximum serum concentration (Cmax) of VIS649 determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants
| μg/mL | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|
| Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participants | 12.600 ± 2.222 | 48.600 ± 11.660 | 135.900 ± 20.380 | 282.600 ± 48.440 | 130.700 ± 20.150 |
The time to the maximum serum concentration (tmax) of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants
| hours | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|
| Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. All Participant | 1.136 (1.12 to 3.11) | 3.045 (1.15 to 3.09) | 3.038 (1.13 to 3.16) | 1.148 (1.11 to 9.11) | 3.053 (1.14 to 25.11) |
Summary of the pharmacokinetic profiles of VIS649 exposure in serum for all participants. AUC0-112 presents the area under the concentration time curve from pre-dose (time 0) to the concentration on day 112. AUC0-last presents the area under the concentration time curve from pre-dose (time 0) to the last quantifiable concentration. AUC0-inf presents the area under the concentration time curve from pre-dose (time 0) extrapolated to infinite time.
| h*μg/mL | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|
| AUC 0-112 days | 1118 ± 209.4 | 11680 ± 3402 | 74500 ± 18570 | 176300 ± 26100 | 57900 ± 18390 |
| AUC 0-last | 885.2 ± 146.2 | 10510 ± 2811 | 72760 ± 19210 | 148900 ± 17460 | 53630 ± 18180 |
| AUC 0-inf | 1118 ± 209.5 | 11670 ± 3403 | 74380 ± 18620 | 187400 ± 35980 | 57910 ± 18390 |
The terminal elimination half life (t1/2) of VIS649 from the concentration-time profile as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.
| hours | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|
| T 1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. All Participants | 60.72 ± 4.35 | 175.20 ± 38.40 | 230.90 ± 76.20 | 670 ± 179.80 | 342.10 ± 91.62 |
The clearance rate (CL) of VIS649 using the exposure calculated to infinity of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants.
| mL/h | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|
| CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. | 31.46 ± 4.544 | 11.70 ± 2.522 | 6.125 ± 2.263 | 4.508 ± 1.375 | 8.724 ± 4.137 |
The volume of distribution of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants.
| mL | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|
| Vd: The Volume of Distribution of VIS649 in Serum Samples. All Participants | 2747 ± 351.6 | 2854 ± 323.5 | 2183 ± 1365 | 4122 ± 780.4 | 3911 ± 828.4 |
The maximum serum concentration (Cmax) of VIS649 determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. Japanese participants
| μg/mL | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 |
|---|---|---|---|---|
| Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Time Profile. Japanese Participants | 11.83 ± 1.172 | 40.13 ± 4.302 | 133.0 ± 12.12 | 249.0 ± 47.84 |
The time to the maximum serum concentration (tmax) of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. Japanese participants.
| hours | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 |
|---|---|---|---|---|
| Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Japanese Participants | 1.136 (1.13 to 3.05) | 3.045 (1.15 to 3.09) | 3.049 (1.14 to 3.16) | 3.064 (1.12 to 9.11) |
AUC0-112 presents the area under the concentration time curve from pre-dose (time 0) to the concentration on day 112. AUC0-last presents the area under the concentration time curve from pre-dose (time 0) to the last quantifiable concentration. AUC0-inf presents the area under the concentration time curve from pre-dose (time 0) extrapolated to infinite time.
| h*μg/mL | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 |
|---|---|---|---|---|
| AUC 0-112 days | 1039 ± 56.05 | 9405 ± 434.5 | 87210 ± 11210 | 185200 ± 32550 |
| AUC 0-last | 820.6 ± 25.48 | 8824 ± 216.3 | 85750 ± 11220 | 150300 ± 21630 |
| AUC 0-inf | 1039 ± 56.01 | 9399 ± 432.1 | 87170 ± 11210 | 203500 ± 47430 |
The terminal elimination half life (t1/2) of VIS649 from the concentration-time profile as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.
| hours | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 |
|---|---|---|---|---|
| T1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. Japanese Participants | 59.24 ± 3.623 | 158.8 ± 14.67 | 189.8 ± 12.65 | 778.4 ± 247.3 |
The clearance rate (CL) of VIS649 using the exposure calculated to infinity of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.
| mL/h | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 |
|---|---|---|---|---|
| CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. Japanese Participants | 28.58 ± 1.794 | 12.26 ± 0.7651 | 4.385 ± 1.242 | 3.618 ± 1.442 |
The volume of distribution of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.
| mL | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 |
|---|---|---|---|---|
| Vd: The Volume of Distribution of VIS649 in Serum Samples. Japanese Participants | 2441 ± 197.9 | 2816 ± 390.3 | 1197 ± 344.5 | 3772 ± 674.7 |
The maximum serum concentration (Cmax) of VIS649 determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.
| μg/mL | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 |
|---|---|---|---|---|---|
| Cmax: Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Non-Japanese Participants | 13.18 ± 2.816 | 54.95 ± 11.57 | 138.1 ± 26.80 | 307.8 ± 34.56 | 130.7 ± 20.15 |
The time to the maximum serum concentration (tmax) of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.
| hours | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 |
|---|---|---|---|---|---|
| Tmax: Time to the Maximum Serum VIS649 Concentration Determined Directly From the Concentration-time Profile. Non-Japanese Participants | 1.170 (1.12 to 3.11) | 2.253 (1.18 to 3.09) | 2.159 (1.13 to 3.06) | 1.142 (1.11 to 3.09) | 3.053 (1.14 to 25.11) |
Summary of the pharmacokinetic profiles of VIS649 exposure in serum for non-Japanese participants. AUC0-112 presents the area under the concentration time curve from pre-dose (time 0) to the concentration on day 112. AUC0-last presents the area under the concentration time curve from pre-dose (time 0) to the last quantifiable concentration. AUC0-inf presents the area under the concentration time curve from pre-dose (time 0) extrapolated to infinite time.
| h*μg/mL | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 |
|---|---|---|---|---|---|
| AUC 0-112 days | 1177 ± 273.4 | 13380 ± 3741 | 64960 ± 17990 | 169700 ± 22790 | 57900 ± 18390 |
| AUC 0-last | 933.6 ± 187.1 | 11780 ± 3283 | 63020 ± 18950 | 147900 ± 17160 | 53630 ± 18180 |
| AUC 0-inf | 1177 ± 273.6 | 13380 ± 3741 | 64790 ± 17980 | 175300 ± 25200 | 57910 ± 18390 |
The terminal elimination half life (t1/2) of VIS649 from the concentration-time profile as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. Non-Japanese participants.
| hours | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|
| T1/2 The Terminal Elimination Half Life of VIS649 in Serum Samples. Non-Japanese Participants | 61.83 ± 5.017 | 187.6 ± 48.26 | 261.8 ± 92.45 | 588.8 ± 57.65 | 342.1 ± 91.62 |
The clearance rate (CL) of VIS649 using the exposure calculated to infinity of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.
| mL/h | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 |
|---|---|---|---|---|---|
| CL: The Clearance of VIS649 in Serum Samples Calculated Using Exposure Extrapolated to Infinity by Dose. Non-Japanese Participants | 33.63 ± 4.959 | 11.27 ± 3.431 | 7.430 ± 1.978 | 5.175 ± 1.004 | 8.724 ± 4.137 |
The volume of distribution of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods.
| mL | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 |
|---|---|---|---|---|---|
| Vd: The Volume of Distribution of VIS649 in Serum Samples. Non-Japanese Participants | 2976 ± 241.0 | 2882 ± 324.3 | 2923 ± 1395 | 4384 ± 837 | 3911 ± 828.4 |
The effect of VIS649 treatment on total IgG levels in serum, weekly observations from baseline to Week 24
| mg/dL | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | Placebo Cohort 5 + Vaccine | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|---|---|
| Baseline | 1138.0 ± 288.08 | 1057 ± 276.8 | 1243 ± 293.55 | 1239.0 ± 269.73 | 1125.0 ± 262.83 | 1080.0 ± 225.92 | 1143.0 ± 213.59 |
| Week 1 | 1152.0 ± 323.58 | 1028.0 ± 257.12 | 1140.0 ± 212.10 | 1142.0 ± 246.84 | 1174.0 ± 298.25 | 1098.0 ± 225.06 | 1092.5 ± 263.15 |
| Week 2 | 1150.5 ± 280.89 | 987.0 ± 271.89 | 1120.0 ± 220.63 | 1108.0 ± 196.16 | 1038.0 ± 240.46 | 1117.0 ± 201.08 | 1053.5 ± 216.66 |
| Week 3 | 1174.0 ± 293.55 | 946.0 ± 242.33 | 1077.0 ± 214.35 | 1076 ± 214.49 | 999.0 ± 212.58 | 1063.0 ± 202.43 | 966.5 ± 235.63 |
| Week 4 | 1184.0 ± 304.93 | 1122.0 ± 264.19 | 1038.0 ± 218.35 | 1053.0 ± 196.39 | 1034 ± 221.08 | 1077.0 ± 186.74 | 1050.0 ± 204.29 |
| Week 5 | 1143.5 ± 237.34 | 994.0 ± 276.89 | 965.0 ± 193.19 | 1005.0 ± 216.24 | 980.0 ± 184.59 | 1094.0 ± 180.03 | 962.0 ± 197.14 |
| Week 6 | 1185.5 ± 295.65 | 1105.0 ± 285.27 | 990.0 ± 216.58 | 1001.0 ± 212.64 | 850.0 ± 191.40 | 1111.0 ± 202.60 | 971.0 ± 194.19 |
| Week 7 | 1195.0 ± 296.0 | 950.5 ± 320.91 | 1005.0 ± 236.55 | 948.0 ± 195.02 | 929.0 ± 184.67 | — | — |
| Week 8 | 1199.5 ± 311.20 | 1022.0 ± 287.47 | 1022.5 ± 220.65 | 974.0 ± 174.83 | 951.5 ± 222.49 | 1117.0 ± 223.8 | 953.0 ± 192.19 |
| Week 10 | 1266.0 ± 301.04 | 1035.0 ± 333.11 | 985.0 ± 234.14 | 1006.0 ± 223.84 | 841.0 ± 196.81 | 1037.0 ± 196.39 | 845.0 ± 211.71 |
| Week 12 | 1215.0 ± 282.42 | 992.0 ± 287.94 | 1036.0 ± 238.29 | 1027.0 ± 168.63 | 718.0 ± 185.80 | 1101.0 ± 205.66 | 970.0 ± 256.28 |
| Week 14 | 1180.0 ± 282.87 | 1038.0 ± 278.83 | 930.0 ± 268.00 | 1071.5 ± 160.55 | 862.0 ± 180.07 | — | — |
| Week 16 | 1147.5 ± 278.04 | 1072.0 ± 242.20 | 934.0 ± 356.27 | 1104.0 ± 233.23 | 876.0 ± 220.38 | 1198.0 ± 156.10 | 1049.0 ± 261.94 |
| Week 20 | 1269.0 ± 279.38 | — | — | 1089.0 ± 260.55 | 1009.0 ± 243.52 | — | — |
| Week 24 | 1250.5 ± 312.89 | — | — | 1075.0 ± 260.55 | 917.5 ± 91.00 | — | — |
The effect of VIS649 treatment on total IgA levels in serum, weekly observations from Baseline to Week 24
| mg/dL | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | Placebo Cohort 5 + Vaccine | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|---|---|
| Baseline | 217.0 ± 70.44 | 202.0 ± 71.69 | 213.0 ± 82.89 | 233.0 ± 136.30 | 243.0 ± 96.48 | 202.0 ± 77.00 | 222.5 ± 65.16 |
| Week 1 | 225.0 ± 68.74 | 165.0 ± 64.10 | 223.0 ± 64.03 | 209.0 ± 120.23 | 214.0 ± 100.42 | 198.0 ± 84.45 | 205.5 ± 57.03 |
| Week 2 | 222.5 ± 74.97 | 151.0 ± 60.23 | 168.0 ± 52.76 | 187.0 ± 111.5 | 174.0 ± 82.09 | 205.0 ± 83.70 | 179.0 ± 48.79 |
| Week 3 | 217.0 ± 73.17 | 147.0 ± 54.07 | 158.0 ± 49.15 | 163.0 ± 103.95 | 155.0 ± 74.91 | 193.0 ± 84.93 | 155.5 ± 41.48 |
| Week 4 | 227.0 ± 76.14 | 169.0 ± 75.99 | 134.0 ± 48.87 | 152.0 ± 87.08 | 146.0 ± 73.05 | 197.0 ± 81.96 | 150.0 ± 42.75 |
| Week 5 | 208.5 ± 71.81 | 164.0 ± 64.44 | 133.0 ± 43.46 | 142.0 ± 87.7 | 128.0 ± 60.93 | 194.0 ± 87.73 | 137.0 ± 38.30 |
| Week 6 | 217.5 ± 71.98 | 167.0 ± 67.82 | 140.0 ± 51.43 | 134.0 ± 76.69 | 116.0 ± 66.61 | 207.0 ± 90.44 | 129.0 ± 37.00 |
| Week 7 | 229.0 ± 68.86 | 152.5 ± 71.68 | 148.0 ± 53.76 | 113.0 ± 74.53 | 110.5 ± 68.99 | — | — |
| Week 8 | 217.0 ± 68.26 | 159.5 ± 74.21 | 148.5 ± 59.02 | 109.0 ± 68.40 | 111.0 ± 66.42 | 210.0 ± 92.31 | 122.0 ± 35.26 |
| Week 10 | 215.5 ± 67.79 | 161.0 ± 59.74 | 171.0 ± 60.80 | 123.0 ± 89.55 | 105.0 ± 61.87 | 207.0 ± 83.97 | 127.0 ± 46.87 |
| Week 12 | 227.5 ± 74.44 | 169.0 ± 65.26 | 171.0 ± 59.46 | 179.0 ± 107.20 | 87.0 ± 59.27 | 192.0 ± 85.87 | 144.0 ± 54.34 |
| Week 14 | 232.0 ± 69.85 | 182.0 ± 70.26 | 164.0 ± 63.82 | 195.5 ± 105.85 | 109.0 ± 56.66 | — | — |
| Week 16 | 220.0 ± 70.88 | 179.0 ± 69.35 | 165.0 ± 89.38 | 158.0 ± 116.54 | 124.0 ± 71.96 | 192.0 ± 85.98 | 169.0 ± 52.57 |
| Week 20 | 243.5 ± 90.16 | — | — | 172.0 ± 117.30 | 153.0 ± 67.43 | — | — |
| Week 24 | 239.0 ± 94.36 | — | — | 164.0 ± 123.92 | 153.5 ± 83.43 | — | — |
The effect of VIS649 treatment on total IgM levels in serum, weekly observations from Baseline to Week 24
| mg/dL | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | Placebo Cohort 5 + Vaccine | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|---|---|
| Baseline | 105.0 ± 43.75 | 116.0 ± 42.77 | 93.0 ± 61.79 | 108.0 ± 49.11 | 133.0 ± 31.67 | 85.0 ± 35.75 | 132.0 ± 34.80 |
| Week 1 | 108.0 ± 38.78 | 117.0 ± 39.91 | 70.0 ± 46.31 | 100.0 ± 46.15 | 128.0 ± 28.80 | 85.0 ± 36.02 | 102.5 ± 31.82 |
| Week 2 | 109.5 ± 42.39 | 91.0 ± 39.04 | 58.0 ± 38.17 | 88.0 ± 43.68 | 94.0 ± 29.89 | 87.0 ± 30.86 | 87.0 ± 25.15 |
| Week 3 | 105.0 ± 39.49 | 85.0 ± 34.49 | 52.0 ± 35.40 | 71.0 ± 38.17 | 80.0 ± 26.13 | 86.0 ± 38.91 | 73.5 ± 24.02 |
| Week 4 | 107.5 ± 43.13 | 84.0 ± 40.45 | 46.0 ± 31.08 | 58.0 ± 34.95 | 75.0 ± 25.32 | 81.0 ± 35.91 | 68.0 ± 20.35 |
| Week 5 | 106.0 ± 39.41 | 83.0 ± 34.54 | 40.5 ± 23.01 | 49.0 ± 32.13 | 60.0 ± 19.85 | 84.0 ± 35.50 | 54.0 ± 15.41 |
| Week 6 | 106.5 ± 42.10 | 92.0 ± 37.21 | 46.0 ± 30.33 | 49 ± 30.35 | 57.0 ± 21.07 | 90 ± 35.22 | 48.0 ± 13.30 |
| Week 7 | 109.5 ± 44.41 | 86.5 ± 35.07 | 48.0 ± 31.14 | 43.0 ± 23.88 | 51.5 ± 18.5 | — | — |
| Week 8 | 110.5 ± 40.73 | 89.5 ± 37.91 | 43.0 ± 26.77 | 46.0 ± 23.80 | 46.0 ± 19.31 | 89.0 ± 33.93 | 42.0 ± 11.07 |
| Week 10 | 104.5 ± 40.87 | 106.0 ± 40.44 | 53.0 ± 29.95 | 49.0 ± 25.15 | 44.0 ± 18.09 | 80.0 ± 32.38 | 49.0 ± 19.53 |
| Week 12 | 113.0 ± 41.39 | 106.0 ± 37.89 | 54.0 ± 36.41 | 73.5 ± 26.46 | 35.0 ± 20.30 | 93.0 ± 41.37 | 63.0 ± 25.09 |
| Week 14 | 113.0 ± 40.09 | 114.0 ± 41.32 | 55.0 ± 33.05 | 82.5 ± 30.31 | 44.0 ± 15.14 | — | — |
| Week 16 | 107.0 ± 40.51 | 127.0 ± 40.51 | 60.0 ± 30.70 | 78.0 ± 39.52 | 55.0 ± 24.08 | 93.0 ± 31.11 | 87.0 ± 30.55 |
| Week 20 | 80.0 ± 42.54 | — | — | 90.0 ± 38.11 | 69.0 ± 23.84 | — | — |
| Week 24 | 89.0 ± 33.56 | — | — | 89.0 ± 40.15 | 74.5 ± 21.08 | — | — |
The effect of VIS649 treatment on the population of circulating CD16 +CD56 (Natural killer) cells in serum for all participants in cohorts 1-4.
| cells/mcl | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 |
|---|---|---|---|---|---|
| Baseline | 122.0 ± 156.14 | 136.0 ± 38.34 | 174.0 ± 88.43 | 107.0 ± 40.82 | 142.0 ± 48.32 |
| Week 4 | 142.5 ± 136.42 | 103.0 ± 46.6 | 144.0 ± 46.13 | 143.0 ± 45.80 | 181.0 ± 82.05 |
| Week 16 | 130.0 ± 30.41 | 150.0 ± 34.55 | 226.0 ± 90.19 | 138.0 ± 49.69 | 153.0 ± 54.99 |
| Week 20 | 204.0 ± 201.87 | — | — | 181.0 ± 58.45 | 189.0 ± 120.94 |
| Week 24 | 195.0 ± 173.776 | — | — | 135.0 ± 41.35 | 270.0 ± 142.83 |
The effect of VIS649 treatment on the population of circulating CD19 (B Cells) in serum for all participants in cohorts 1-4.
| cells/uL | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 |
|---|---|---|---|---|---|
| Baseline | 165 ± 128.25 | 193.0 ± 23.72 | 244.0 ± 89.67 | 268.0 ± 79.96 | 179.0 ± 49.44 |
| Week 4 | 187.0 ± 73.92 | 206.0 ± 34.69 | 204.0 ± 78.55 | 294.0 ± 129.97 | 202.0 ± 67.12 |
| Week 16 | 166.0 ± 93.65 | 226.0 ± 51.84 | 209.0 ± 98.99 | 359.0 ± 113.22 | 167.0 ± 55.86 |
| Week 20 | 277.5 ± 70.72 | — | — | 320.0 ± 146.34 | 190.0 ± 72.04 |
| Week 24 | 270.5 ± 76.49 | — | — | 267.0 ± 65.38 | 239.0 ± 76.41 |
The effect of VIS649 treatment on the population of circulating CD4 T cells in serum for all participants in cohorts 1-4.
| cells/uL | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 |
|---|---|---|---|---|---|
| Baseline | 679.0 ± 178.00 | 592.0 ± 156.93 | 755.0 ± 145.8 | 553.0 ± 288.67 | 698.0 ± 166.09 |
| Week 4 | 601.5 ± 91.92 | 631.0 ± 182.52 | 733.0 ± 194.08 | 592.0 ± 337.55 | 813.0 ± 233.06 |
| Week 16 | 608.0 ± 153.29 | 649.0 ± 198.87 | 718 ± 127.74 | 606.0 ± 347.79 | 799.0 ± 208.09 |
| Week 20 | 895.0 ± 279.84 | — | — | 630.0 ± 300.58 | 738.0 ± 255.19 |
| Week 24 | 917.0 ± 245.42 | — | — | 499.0 ± 196.44 | 992.0 ± 374.77 |
The effect of VIS649 treatment on the population of circulating CD3 T cells in serum for all participants in cohorts 1-4.
| cells/uL | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 |
|---|---|---|---|---|---|
| Baseline | 1147.5 ± 313.07 | 1118.0 ± 284.46 | 1218.0 ± 200.20 | 985.0 ± 365.33 | 991.0 ± 318.12 |
| Week 4 | 1074.0 ± 186.09 | 993.0 ± 292.84 | 1110.0 ± 358.19 | 1018.0 ± 407.5 | 1226.0 ± 433.57 |
| Week 16 | 1025.0 ± 300.38 | 1085.0 ± 220.178 | 1082.0 ± 140.94 | 1208.0 ± 437.35 | 1270.0 ± 367.31 |
| Week 20 | 1565.0 ± 340.67 | — | — | 970.0 ± 387.46 | 1139.0 ± 558.77 |
| Week 24 | 1644.5 ± 299.56 | — | — | 868.0 ± 207.34 | 1259.0 ± 722.50 |
The effect of VIS649 treatment on the population of circulating CD8 T cells in serum for all participants in cohorts 1-4.
| cells/uL | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 |
|---|---|---|---|---|---|
| Baseline | 483.5 ± 145.06 | 442.0 ± 165.29 | 356.0 ± 103.21 | 373.0 ± 108.08 | 327 ± 199.67 |
| Week 4 | 424.0 ± 112.24 | 338.0 ± 135.81 | 373.0 ± 152.41 | 370.0 ± 129.55 | 397.0 ± 246.05 |
| Week 16 | 373.0 ± 166.71 | 471.0 ± 66.20 | 349.0 ± 66.96 | 391.0 ± 137.52 | 461.0 ± 210.56 |
| Week 20 | 623.0 ± 110.15 | — | — | 362.0 ± 145.02 | 416.0 ± 359.67 |
| Week 24 | 702.0 ± 86.56 | — | — | 322.0 ± 66.27 | 342.0 ± 443.94 |
Summary of Anti -VIS649 anti-drug antibodies (ADA) by treatment group, all participants
| Participants | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | Placebo Cohort 5 + Vaccine | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|---|---|
| Baseline — Negative | 8 | 7 | 7 | 7 | 7 | 5 | 10 |
| Baseline — Positive | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Week 4 — Negative | 8 | 7 | 7 | 7 | 7 | 5 | 8 |
| Week 4 — Positive | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Week 8 — Negative | 8 | 6 | 5 | 7 | 6 | 5 | 8 |
| Week 8 — Positive | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Week 16 — Negative | 8 | 7 | 3 | 5 | 3 | 5 | 7 |
| Week 16 — Positive | 0 | 0 | 2 | 2 | 4 | 0 | 2 |
Summary of Anti -VIS649 antibody (ADA) titer by treatment, all participants with ADA positive results
| titer | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | Placebo Cohort 5 + Vaccine | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|---|---|
| Week 4 | — | — | — | — | — | — | 1.0 |
| Week 8 | — | — | 0.0 | — | — | — | 0.0 |
| Week 16 | — | — | 32.0 ± 45.25 | 18.0 ± 19.80 | 6.0 ± 6.83 | — | 2.0 ± 2.83 |
The maximum serum concentration (Cmax) of VIS649 determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 status (positive or negative).
| μg/mL | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|
| Negative | 12.600 ± 2.222 | 48.660 ± 12.040 | 134.100 ± 23.730 | 259.000 ± 65.110 | 136.300 ± 18.420 |
| Positive | — | 48.450 ± 15.340 | 140.500 ± 13.440 | 300.300 ± 29.900 | 117.700 ± 21.140 |
The time to the maximum serum concentration (tmax) of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 status (positive or negative).
| hours | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|
| Negative | 1.136 (1.12 to 3.11) | 1.434 (1.15 to 3.09) | 3.038 (1.14 to 3.16) | 3.064 (1.11 to 9.11) | 3.049 (1.14 to 25.11) |
| Positive | — | 3.058 (3.05 to 3.07) | 2.089 (1.13 to 3.05) | 1.142 (1.12 to 3.09) | 3.055 (3.05 to 3.07) |
Summary of the pharmacokinetic profiles of VIS649 exposure in serum for all participants based on their anti-VIS649 antibody status (negative/positive). AUC0-112 presents the area under the concentration time curve from pre-dose (time 0) to the concentration on day 112. AUC0-last presents the area under the concentration time curve from pre-dose (time 0) to the last quantifiable concentration. AUC0-inf presents the area under the concentration time curve from pre-dose (time 0) extrapolated to infinite time.
| h*μg/mL | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|
| AUC 0-112 days--ADA Negative participants | 1118 ± 209.400 | 12270 ± 3876 | 71440 ± 19090 | 177700 ± 31330 | 56390 ± 17870 |
| AUC 0-112 days--ADA Positive participants | — | 10200 ± 1805 | 82120 ± 21210 | 175300 ± 26540 | 61450 ± 23170 |
| AUC 0-last--ADA negative participants | 885.2 ± 146.200 | 10750 ± 3277 | 69700 ± 20050 | 145100 ± 16950 | 51550 ± 17860 |
| AUC 0-last--ADA positive participants | — | 9922 ± 1863 | 80410 ± 21040 | 151800 ± 19810 | 58500 ± 21880 |
| AUC 0-inf--ADA negative participants | 1118 ± 209.500 | 12260 ± 3878 | 71340 ± 19120 | 194300 ± 49280 | 56450 ± 17930 |
| AUC 0-inf--ADA positive participants | — | 10200 ± 1806 | 81980 ± 21350 | 182100 ± 29760 | 61320 ± 23060 |
The terminal elimination half life (t1/2) of VIS649 from the concentration-time profile as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 antibody status (negative/positive).
| hours | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|
| T1/2 ADA Negative participants | 60.720 ± 4.346 | 192.600 ± 29.040 | 224.600 ± 85.810 | 738.4 ± 281.800 | 335.300 ± 96.780 |
| T1/2 ADA Positive participants | — | 131.900 ± 14.750 | 246.600 ± 68.520 | 618.8 ± 59.450 | 358.200 ± 95.520 |
The clearance rate (CL) of VIS649 using the exposure calculated to infinity of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 antibody status (positive or negative)..
| mL/h | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|
| CL--ADA negative participants | 31.460 ± 4.544 | 10.870 ± 2.023 | 6.536 ± 2.203 | 4.019 ± 1.500 | 9.272 ± 4.765 |
| CL--ADA positive participants | — | 13.750 ± 3.153 | 5.097 ± 2.890 | 4.875 ± 1.364 | 7.445 ± 2.324 |
The calculated volume of distribution of VIS649 as determined by an electrochemiluminescence (ECL) immunoassay and analyzed by standard non-compartmental pharmacokinetic methods. All participants by anti-VIS649 antibody status (positive or negative).
| mL | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|
| Vd--ADA negative | 2747 ± 351.600 | 2961 ± 287.200 | 2274 ± 1474 | 3894 ± 548.8 | 4026 ± 983.8 |
| Vd--ADA positive | — | 2584 ± 307.500 | 1956 ± 1532 | 4292 ± 962.6 | 3641 ± 171.100 |
Collected over From Day -1 to Day 112. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pooled Placebo | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| VIS649 Cohort 1 | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| VIS649 Cohort 2 | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| VIS649 Cohort 3 | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| VIS649 Cohort 4 | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Placebo Cohort 5 + Vaccine | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| VIS649 Cohort 5 + Vaccine | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Event | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | Placebo Cohort 5 + Vaccine | VIS649 Cohort 5 + Vaccine |
|---|---|---|---|---|---|---|---|
| Diarrhoea, Food poisoning, Constipation, or VomitingGastrointestinal disorders | 1/8 | 0/7 | 1/7 | 1/7 | 2/7 | 2/5 | 0/10 |
| Infections and infestationsInfections and infestations | 1/8 | 1/7 | 1/7 | 1/7 | 0/7 | 2/5 | 1/10 |
| Dizziness, Headache, Head discomfort, Migraine, Somnolence, Syncope, or Taste disorderNervous system disorders | 1/8 | 1/7 | 2/7 | 2/7 | 1/7 | 0/5 | 0/10 |
| General disorders and administration site conditionsGeneral disorders | 2/8 | 0/7 | 1/7 | 1/7 | 1/7 | 1/5 | 1/10 |
| Rash papularSkin and subcutaneous tissue disorders | 0/8 | 0/7 | 0/7 | 0/7 | 1/7 | 1/5 | 0/10 |
| Back pain or MyalgiaMusculoskeletal and connective tissue disorders | 0/8 | 0/7 | 1/7 | 1/7 | 0/7 | 0/5 | 0/10 |
| BlepharitisEye disorders | 0/8 | 0/7 | 0/7 | 0/7 | 1/7 | 0/5 | 0/10 |
| Decreased appetiteMetabolism and nutrition disorders | 0/8 | 0/7 | 0/7 | 0/7 | 1/7 | 0/5 | 0/10 |
| Menopausal symptomsReproductive system and breast disorders | 0/8 | 0/7 | 1/7 | 0/7 | 0/7 | 0/5 | 0/10 |
| SunburnInjury, poisoning and procedural complications | 1/8 | 0/7 | 0/7 | 0/7 | 0/7 | 0/5 | 1/10 |
| Age, Continuous(years) | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | Placebo Cohort 5 + Vaccine | VIS649 Cohort 5 + Vaccine | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 32.6 ± 9.24 | 29.4 ± 6.70 | 40.4 ± 11.70 | 41.0 ± 9.63 | 40.9 ± 11.87 | 33.4 ± 8.44 | 30.9 ± 7.28 | 35.3 ± 9.99 |
| Sex: Female, Male(Participants) | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | Placebo Cohort 5 + Vaccine | VIS649 Cohort 5 + Vaccine | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 3 | 5 | 5 | 5 | 4 | 3 | 4 | 29 |
| Male | 5 | 2 | 2 | 2 | 3 | 2 | 6 | 22 |
| Race (NIH/OMB)(Participants) | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | Placebo Cohort 5 + Vaccine | VIS649 Cohort 5 + Vaccine | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 4 | 3 | 3 | 3 | 3 | 0 | 0 | 16 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 3 | 1 | 3 | 3 | 7 | 22 |
| White | 1 | 2 | 1 | 3 | 1 | 2 | 3 | 13 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | Placebo Cohort 5 + Vaccine | VIS649 Cohort 5 + Vaccine | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 8 | 7 | 7 | 7 | 7 | 5 | 10 | 51 |
| Height (cm)(cm) | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | Placebo Cohort 5 + Vaccine | VIS649 Cohort 5 + Vaccine | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 170.9 ± 8.22 | 165.4 ± 10.11 | 165.3 ± 11.91 | 166.4 ± 7.93 | 167.1 ± 13.04 | 167.8 ± 10.33 | 174.9 ± 11.82 | 168.7 ± 10.64 |
| Weight (kg)(Kg) | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | Placebo Cohort 5 + Vaccine | VIS649 Cohort 5 + Vaccine | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 73.53 ± 15.378 | 69.64 ± 11.563 | 66.3 ± 16.236 | 70.03 ± 11.517 | 67.24 ± 12.699 | 71.36 ± 4.225 | 74.33 ± 10.624 | 70.60 ± 12.097 |
| Body Mass Index(kg/m2) | Pooled Placebo | VIS649 Cohort 1 | VIS649 Cohort 2 | VIS649 Cohort 3 | VIS649 Cohort 4 | Placebo Cohort 5 + Vaccine | VIS649 Cohort 5 + Vaccine | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 25.10 ± 4.275 | 25.39 ± 2.812 | 23.96 ± 3.625 | 24.86 ± 4.156 | 24.00 ± 2.864 | 25.52 ± 2.906 | 24.52 ± 2.011 | 24.67 ± 3.145 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2018 to primary completion in Aug 2019, 10 months.
Results were first posted in Mar 2025, 5 years 7 months after primary completion.
Of 22 phase 1 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 10 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc. →